大会第二天
Session A会场和Session B会场
Those present at Session A on the second day include: Wu Hao, Director of Drug Evaluation Department, Shanghai
Center for Drug Evaluation and Inspection; Peter Peng, GM of JHL Wuhan and EVP of Regulatory Affairs, JHL; Dr.
Mark Demesmaeker, Head of Data Analytics, Sartorius; Roman Necina, SVP Process Development & Technical Services,
Shire; Trevor Marshall, Director Global Engineering, Zenith Technologies; Zhu Huilin, Ph.D, Director of Cell
Culture Process Development, WuXi Biologics; Li Xiaoxiang, SUT Validation Lab Manager, Pall Corporation; Liu
Xun, Vice General Manager, Hengrui Medicine; Stefano Selvatici (Marchesini Group); Alberto Negri (Sea Vision);
Li Shude, Senior Vice President, Mab-Venture Biopharma Co. Ltd.; and Alex Marchut, Principal Scientist,
Technical Operations, Janssen Supply Chain.
Many experts were invited to Session B on the same day to deliver keynote speeches, including Dr. Zhao Qinghai,
Vice president, Technical Development & Manufacturing, Forty Seven lnc.; Fang Jianmin, CEO, MabPlex
International, Inc.; Pascal Wotling, Head External Supply Operations, Region APMA chez, Novartis; Connery Lin,
Ph.D., Senior Director, Antibody Drug Downstream Process Development GenScript, GenScript Biotech Corp; Shi
Liming, Executive Director, CMAB Biopharma; John Alter, VP Global Health & Value, Global Established Pharma
Business Unit Pfizer; Xie Yansheng from Zhejiang Teruisi Pharmaceutical Co., Ltd.; Justin Wang, a Partner based
in L.E.K.'s Shanghai office and a leader in L.E.K. China's Life Science practice; Guo Bingshi, PhD, MS, CSO of
I-Mab Biopharma.
In the panel session "enterprise investment in digital technology will probably become inevitable" moderated by
Liu Kang from GE Healthcare, guest representatives, including Huaota Biopharm CEO Zhu Xiangyang, Head of
Manufacturing Sciences in Biogen Jiang Canping, Head of Data Analytics in Sartorius Dr. Mark Demesmaeker,
Biopharming VP of Qilu Pharmacutical Liu Ding, had an in-depth discussion on the digital transformation of
enterprises. In another panel discussion focusing on the rising of "Rookie," the key factors and new thinking in
the transformation of biopharmaceutical production technology, Hengrui Medicine Vice General Manager Liu Xun was
invited to be the chair. WuXi AppTec Vice President Wang Zihong, Director of Global Engineering of Zenith
Technologies Trevor Marshall, United BioPharma Inc. CEO Lin Shujing and Shi Tao from Pall Corporation had a
thorough discussion regarding the expectations for regulations when embracing new technologies, the progress of
advanced equipment standardization, and the challenges and opportunities faced by suppliers and
biopharmaceutical companies. The Biopharma 4.0 Leadership Roundtable was hosted by Innovent SVP Xu Wei. CBMG CEO
Liu Bizuo, VP and Head of International Business Development of Salubris Dr. Sam Murphy, SanPower Group CSO Du
Zhou, BeiGene Manufacturing VP Liu Jian had heated discussions on topics such as "Pharmaceutical giants are
losing their strength, small and beautiful enterprises gradually become popular", "Will it be a new way out for
traditional pharmaceutical companies to invest billions in bio-drugs?" and "Why are start-up biopharmaceutical
enterprises favored over others?" The guests on and off the stage frequently interact with each other, evoking
warm response.
The summit also received strong support from many leading companies in the industry, such as Emerson, GE
Healthcare, Saint-Gobain, Pall Corporation, Sartorius, Zenith Technologies, GenScript Biotech Corp, MabPlex,
Marchesini Group, Avantor, Thermo Fisher Scientific, Boehringer-Ingelheim, Siemens, Tofflon, Mettler Toledo,
Olymstar, Haier Biomedical, Cole-Parmer, West Pharmaceutical Services, Rieckermann, and Jet Bio-Filtration, and
the support from Watson-Marlow and other sponsors. Although lasting only for two days, the summit has received
warm response and positive feedback from the attendees and closed successfully. The China International
Biopharma 4.0 Summit will continue to bring you wonderful experience. We are looking forward to your future
participation!